MAP2K7 and Miyoshi myopathy: By undertaking a drug discovery approach, we developed DTP3, which disrupts the GADD45β/MKK7 interaction and kills MM cells effectively by inducing MKK7/JNK-dependent apoptosis, without overt toxicity to normal tissues [5].